Form 10-Q BIOMARIN PHARMACEUTICAL For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $126 at SunTrust Robinson Humphrey
August 3, 2018 2:32 PM EDTSunTrust Robinson Humphrey raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $126.00 (from $121.00) while maintaining a Buy rating.
Analyst Edward Nash commented, "BioMarin reported a strong 2nd quarter. All but Kuvan's net product sales beat Street consensus. Prior guidance... More
